Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Guidelines for Writing Outcome01:11

Guidelines for Writing Outcome

When developing expected outcomes for a patient care plan, the nurse should adhere to the following recommendations:
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care evaluation by...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.

Endocrine-related cancer·2026
Same author

Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026
Same author

Late Recurrences Beyond Five Years in Salivary Adenoid Cystic Carcinoma: Implications for Long-Term Surveillance.

OTO open·2026
Same author

Management of Differentiated Thyroid Cancer.

The New England journal of medicine·2026
Same author

Genome-wide variation in cell-free DNA end-motif entropy predicts immunotherapy response in head and neck cancer.

The Journal of clinical investigation·2026
Same author

A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib.

Thyroid : official journal of the American Thyroid Association·2026

Related Experiment Video

Updated: Jun 21, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K

Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.

Andrew G Gianoukakis1, Jennifer H Choe2, Daniel W Bowles3

  • 1The Lundquist Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA, Torrance, California, USA.

European Thyroid Journal
|December 14, 2023
PubMed
Summary

Active surveillance is a viable option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer. However, early multi-kinase inhibitor therapy may benefit some patients, necessitating further research for optimal treatment selection.

Keywords:
ATA risk stratificationactive surveillanceadvanced differentiated thyroid cancerreal-world evidence

More Related Videos

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

555
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K

Related Experiment Videos

Last Updated: Jun 21, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

5.6K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

555
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

1.7K

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Differentiated thyroid cancer (DTC) that is refractory to radioactive iodine (RAI-R) presents treatment challenges.
  • The optimal timing for initiating multi-kinase inhibitors (MKIs) in patients with progressive RAI-R DTC is not well-defined.
  • Real-world practice patterns and outcomes for asymptomatic, progressive RAI-R DTC patients are evaluated.

Purpose of the Study:

  • To compare real-world practice patterns of MKI therapy versus active surveillance in patients with progressive RAI-R DTC.
  • To evaluate the time to symptomatic progression (TTSP) in patients managed with active surveillance versus early MKI initiation.
  • To identify potential differences in outcomes between US and non-US patient populations.

Main Methods:

  • Prospective, non-interventional, open-label study involving patients with progressive RAI-R DTC.
  • Patients were assigned by physicians to either MKI therapy (cohort 1) or active surveillance (cohort 2).
  • Primary endpoint was time to symptomatic progression (TTSP); 36-month rates were calculated for inestimable endpoints.

Main Results:

  • Of 647 patients, 478 (74%) were in the active surveillance cohort and 169 (26%) received MKI therapy.
  • US patients had a higher rate of active surveillance (92.6%) compared to non-US patients (66.9%).
  • In cohort 2, 36-month TTSP rates were similar (65.6% US vs. 66.5% non-US); however, later MKI treatment in cohort 2 showed lower TTSP rates (30.8% US vs. 55.8% non-US).

Conclusions:

  • Active surveillance is a feasible management strategy for asymptomatic patients with progressive RAI-R DTC.
  • Early MKI intervention may be more beneficial for certain patient subgroups.
  • Further research is required to identify specific patient characteristics that predict optimal response to active surveillance versus early MKI therapy.